key: cord-0815617-5ispf96z authors: Rahman, Tanvir; Alayo, Quazim A; Chaudhary, Sibgha G; Moghadam, Reihaneh C; German, Matthew L; Ettinger, Neil A; Leidenfrost, Jeremy E; Cranston-D'amato, Hope A; Rinder, Morton R; Donnelly, Julianne E title: STEMI associated with SARS-CoV-2 infection and the use of ECMO as a potential therapeutic approach in addition to the PCI date: 2021-03-08 journal: Oxf Med Case Reports DOI: 10.1093/omcr/omaa148 sha: 0bfb7d52600c32288be22a7b5836e5835d39dcb6 doc_id: 815617 cord_uid: 5ispf96z A 55-year-old male presented to the emergency department with the complaints of chest pain that started 4 h before presentation. Pain was located over the anterior chest, 5 out of 10 intensity, with radiation to the left arm. Chest x-ray on admission showed severe diffuse bilateral pulmonary infiltrates concerning for COVID-19 pneumonia. Electrocardiogram showed inferior and lateral ST-segment elevation compatible with acute inferolateral myocardial infarction. Successful percutaneous coronary intervention (PCI) of the proximal and mid-right coronary artery using the balloon angioplasty and drug-eluting stent was performed. Post-PCI stenosis was 0% with a thrombolysis in myocardial infarction (TIMI) flow of 3. Five-day course of azithromycin and hydroxychloroquine was completed with no improvement overall. Patient received two doses of 400 mg of tocilizumab intravenously on hospital days 5 (HD#5) and #6. The patient was proned, on FiO(2) 100%, PEEP 15 cm H(2)O, on epoprostenol sodium and paralytics and eventually received venovenous ECMO, which improved outcome. Thrombosis with severe acute respiratory syndrome coronavirus infection has been reported in the past [1] , which is believed to be caused from exaggerated cytokine response from the viral infection. Here, we present a case with severe acute respiratory syndrome coronavirus −2 (SARS-CoV-2) infection presenting with right coronary artery (RCA) thrombosis. A 55-year-old male presented to the emergency department in April 2020, with the complaints of sudden-onset, left-anterior chest pain that started 4 h before presentation. Pain was 5 out of 10 in intensity, with radiation to the left arm, and no associated shortness of breath (SOB). He also reported a 2-week history of dry cough and fever. Patient is a police officer, and two of his coworkers tested positive for SARS-CoV-2 infection. Past medical history significant for hypertension, hyperlipidemia, coronary artery disease (CAD) status post-percutaneous coronary intervention (PCI) with drug-eluting stent (DES) in 2005 and coronary artery bypass graft × 4 in 2008, untreated type II diabetes mellitus and polycythemia. Differential diagnosis included acute coronary syndrome, acute pulmonary embolism, pneumonia due to corona virus disease-2019 (COVID-19), acute on chronic heart failure exacerbation, myocarditis, pericarditis, tension pneumothorax and costochondritis. Chest X-ray (CXR) on admission showed severe diffuse bilateral pulmonary infiltrates with air bronchograms (Fig. 1) , which was concerning for COVID-19 pneumonia. Electrocardiogram (ECG) showed acute inferolateral ST-segment elevation myocardial infarction (STEMI). ST-segment depression in V1 and V2 suggested posterior myocardial injury (Fig. 2) . Initial cardiac troponin I (TnI) was 0.02 ng/L (reference range < 19 ng/L) at 7 h. Reverse transcription-polymerase chain reaction was positive for SARS-CoV-2. On physical examination, he was diaphoretic, heart rate 100 beats/minute (bpm), elevated blood pressure at 148/100 mm hg and hypoxic on room air. Repeat TnI was elevated at 19 ng/L at 11:40 h. STEMI protocol was activated and patient was taken to the cardiac catheterization lab. Left heart catheterization with coronary angiography and graft injection showed 90% stenosis of both proximal and mid-portion of the RCA with a TIMI flow of 3. Saphenous vein grafts to mid-diagonal artery and midobtuse marginal artery were patent. Left ventricular ejection fraction was 55%. Successful PCI of the proximal and mid-RCA using the balloon angioplasty and DES was performed. Post-PCI stenosis was 0% with TIMI flow of 3 (Fig. 3) . Severe hypoxia out of proportion to the CAD was noted during the procedure. ECG post-PCI showed near normalization of the ST-segment elevation (Fig. 4) . He was given prasugrel and started on eptifibatide drip and was transferred to the medical intensive care unit. Even though his chest pain improved following the PCI, he was still complaining of SOB requiring up to 10 L of oxygen by highflow nasal cannula (HFNC). Because of the rapid and abrupt decompensation, he was intubated on the hospital day 1 (HD#1). Five-day course of azithromycin and hydroxychloroquine was completed with no significant improvement. Patient received two doses of intravenous tocilizumab on HD#5 and #6. Refractory hypoxemia (arterial blood gases: pH 7.41, pCO 2 53.4, pO 2 72.4, HCO 3 34) persisted despite maximal ventilator settings (proned, FiO 2 100%, PEEP 15 cm H 2 O, epoprostenol sodium and paralytics). Therefore, given his young age and otherwise healthy status, it was decided to place him on venovenous (VV) ECMO support. He was cannulated at the bedside with 25 French inferior vena cava cannula and 25 French right internal jugular cannula. Flow of 6 L/minute was provided with FiO 2 of 100% and sweep of 8. Ventilator mode was set to pressure-regulated volume control, very low tidal volume at 300 mL, 15 breaths/min, minute volume 4.5 L/min, PEEP 12 cm H 2 O, FiO 2 60%. On HD#9, interleukin 6 (IL-6) level was 86.9 pg/ml (a 12-fold decrease), and ECMO was decannulated on the HD#13. He was extubated on the HD#16 and was breathing on 10 L oxygen by HFNC. He remained only on dexmedetomidine, was awake and followed commands. On HD#17, oxygen weaned to 4 L, and on HD#18, he was off of oxygen and breathing on room air. He was discharged to home on HD#24. Inflammatory markers trended down (Table 1 ) and the IL-6 level remained low at 141 pg/ml. CXR improved significantly on discharge when compared to that of admission (Fig. 5) . He is doing well without any residual symptoms as we write this report. SARS-CoV-2 uses angiotensin-converting enzyme-2 receptor as a portal of entry into target cells, including endothelium and cardiac myocytes making heart tissue a common target for the SARS-CoV-2 [2] . Several observational studies have reported cardiovascular complications of SARS-CoV-2 infection, including myocardial injury and myocarditis, acute coronary syndrome, acute heart failure, cardiomyopathies, elevated troponins, cardiac dysrhythmias and venous thromboembolic events [3, 4] . Little is known about the pathophysiology of acute coronary syndrome (ACS) in SARS-CoV-2 infection. Multiple mechanisms have been postulated including direct myocardial injury, plaque rupture due to severe acute inflammation, aggravation of preexisting CAD, altered myocardial demandsupply ratio, coronary thrombosis. It is plausible that, the COVID-19 infection facilitated the thrombosis in the RCA by inducing a hypercoagulable state [5] in a patient already prone to ACS from preexisting CAD and polycythemia (admission hemoglobin 17.9 g/dl and hematocrit 51.1%). IL-6 plays a significant role to cause 'cytokine storm' in acute inflammatory settings and reported to be associated with myocardial injury [6] . In our patient, administration of tocilizumab and VV ECMO was associated with a positive outcome with significant decrease in the inflammatory markers and IL-6 possibly by slowing down the vicious inflammatory process. There is emerging evidence on the beneficial effect of ECMO in the treatment of COVID-19 including improved survival rate [7, 8] , and similar mortality in patients with severe adult respiratory distress syndrome regardless of the COVID-19 status [9] . Cui et al. reported an increased incidence of venous thromboembolism (VTE) and associated mortality in their patient population with COVID-19 [10] . Our patient was discharged on apixaban in addition to clopidogrel, rosuvastatin and metoprolol due to this potential risk of developing VTE from SARS-CoV-2 infection and having a recent RCA thrombosis. Severe acute respiratory syndrome and venous thromboembolism in multiple organs Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Thromboinflammation and the hypercoagulability of COVID-19 IL-6 signalling in patients with acute STelevation myocardial infarction Extracorporeal membrane oxygenation support in severe COVID-19 Extracorporeal membrane oxygenation for coronavirus disease Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the extracorporeal life support organization registry Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia None. None. None. No ethical approval was needed for this case report. Used for educational purpose with full confidentiality of patient information. Patient's written consent was obtained and submitted. Julianne E. Donnelly, MD.